COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08SJT
|
|||
Drug Name |
Sarilumab
|
|||
Synonyms |
Kevzara
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | |
Other Indication | Rheumatoid arthritis | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Company |
Sanofi/Regeneron
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN interleukin-6 receptor (IL6R) | Target Info | Blocker | [3], [4] |
IL-6 plays a central role in cytokine storm and significantly elevated in critically ill COVID-19 patients. Sarilumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04327388) Sarilumab COVID-19 | |||
2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
3 | IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. | |||
4 | WHAT IS KEVZARA |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.